RRAS2 and cancer: In any case, the results presented here indicate that R-RAS2 and RAS proteins are likely to engage common effectors using different subcellular platforms and upstream signals, a finding that might have important repercussions for our understanding of how each of those proteins work in the context of both cancer and Noonan syndrome.